Glück Conviction Score™ ⓘ
KALV
KalVista Pharmaceuticals, Inc.
Effektiv: Schwach
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
49,3
37 neu, 64 erhöht, 321,3M $ netto
Aktivist
29,3
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 24.01 | +12.4 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 16.84 | +60.3 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 26.51 | EMA50: 24.25 | |
| MACD-Histogramm | Bärisch | 10 % | -0.232 | Bearisch | |
| RSI(14) | Bärisch | 10 % | 75.9 | Überkauft | |
| Stoch %K(14) | Bärisch | 5 % | 100.0 | Überkauft | |
| ADX(14)+DI | Bullisch | 10 % | 56.8 | +DI: 40.5 / −DI: 9.1 | |
| Z-Score(60) | Neutral | 5 % | 1.02 | In Range | |
| 52W-Position | Bullisch | 5 % | 100.0 % | Hoch 27.00 / Tief 10.76 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 88.8 % | Upper 27.04 / Mid 26.86 / Lower 26.67 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.2125 | R²=0.82 / annualisiert +234.1 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -33.800 | 26,78 | -905.224,84 | -577,4% | |
| 2026-05-26 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -1.966 | 26,78 | -52.645,15 | -33,6% | |
| 2026-05-26 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.239 | 26,78 | -59.955,49 | -38,2% | |
| 2026-05-26 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -1.489 | 26,78 | -39.872,14 | -25,4% | |
| 2026-05-22 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -1.861 | 26,78 | -49.845,77 | -31,8% | |
| 2026-05-22 | Piekos Brian | Officer, Chief Financial Officer | Open Market Sale | -1.489 | 26,78 | -39.881,97 | -25,4% | |
| 2026-05-22 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.685 | 26,78 | -71.916,11 | -45,9% | |
| 2026-05-22 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10.926 | 26,78 | -292.646,35 | -186,7% | |
| 2026-05-22 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -2.358 | 26,78 | -63.157,62 | -40,3% | |
| 2026-05-18 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -1.108 | 26,76 | -29.650,08 | -18,9% | |
| 2026-05-18 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -1.129 | 26,76 | -30.212,04 | -19,3% | |
| 2026-05-18 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.032 | 26,76 | -27.616,32 | -17,6% | |
| 2026-05-12 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3.322 | 26,71 | -88.730,62 | -56,6% | |
| 2026-04-17 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -9.550 | 20,22 | -193.065,67 | -123,1% | |
| 2026-04-17 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.686 | 20,22 | -54.300,98 | -34,6% | |
| 2026-04-17 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -1.862 | 20,22 | -37.642,75 | -24,0% | |
| 2026-04-17 | Piekos Brian | Officer, Chief Financial Officer | Open Market Sale | -1.862 | 20,22 | -37.642,75 | -24,0% | |
| 2026-03-26 | Venrock Healthcare Capital Partners III, L.P. | 10% Owner | Open Market Sale | -15.417 | 18,82 | -290.147,94 | -185,1% | |
| 2026-03-26 | Venrock Healthcare Capital Partners III, L.P. | 10% Owner | Open Market Sale | -21.386 | 17,76 | -379.815,36 | -242,3% | |
| 2026-03-26 | Venrock Healthcare Capital Partners III, L.P. | 10% Owner | Open Market Sale | -3.183 | 19,12 | -60.858,96 | -38,8% | |
| 2026-03-25 | Venrock Healthcare Capital Partners III, L.P. | 10% Owner | Open Market Sale | -160 | 17,53 | -2.804,80 | -1,8% | |
| 2026-03-25 | Venrock Healthcare Capital Partners III, L.P. | 10% Owner | Open Market Sale | -174.485 | 16,95 | -2.957.520,75 | -1886,4% | |
| 2026-03-09 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -6.693 | 16,08 | -107.632,81 | -68,7% | |
| 2026-02-23 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -3.975 | 15,57 | -61.878,03 | -39,5% | |
| 2026-02-23 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -4.347 | 15,57 | -67.668,88 | -43,2% | |
| 2026-02-23 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5.354 | 15,57 | -83.344,65 | -53,2% | |
| 2026-02-23 | Piekos Brian | Officer, Chief Financial Officer | Open Market Sale | -1.767 | 15,57 | -27.506,54 | -17,5% | |
| 2026-02-23 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10.034 | 15,57 | -156.197,27 | -99,6% | |
| 2026-02-18 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -1.109 | 15,00 | -16.635,00 | -10,6% | |
| 2026-02-18 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -1.038 | 15,00 | -15.570,00 | -9,9% | |
| 2026-02-18 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.163 | 15,00 | -17.445,00 | -11,1% | |
| 2026-02-12 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3.354 | 15,70 | -52.657,80 | -33,6% | |
| 2025-12-08 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7.294 | 16,51 | -120.423,94 | -76,8% | |
| 2025-11-24 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5.296 | 13,45 | -71.236,50 | -45,4% | |
| 2025-11-24 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -3.813 | 13,45 | -51.288,66 | -32,7% | |
| 2025-11-24 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10.940 | 13,45 | -147.153,94 | -93,9% | |
| 2025-11-24 | Piekos Brian | Officer, Chief Financial Officer | Open Market Sale | -4.471 | 13,45 | -60.139,42 | -38,4% | |
| 2025-11-24 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -4.331 | 13,45 | -58.256,28 | -37,2% | |
| 2025-11-18 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -4.466 | 14,48 | -64.665,00 | -41,2% | |
| 2025-11-18 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -3.075 | 14,48 | -44.524,46 | -28,4% | |
| 2025-11-18 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -2.683 | 14,48 | -38.848,23 | -24,8% | |
| 2025-11-12 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3.328 | 11,55 | -38.438,40 | -24,5% | |
| 2025-09-08 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7.294 | 15,84 | -115.536,96 | -73,7% | |
| 2025-08-25 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -1.480 | 13,42 | -19.861,60 | -12,7% | |
| 2025-08-25 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -1.954 | 13,42 | -26.222,68 | -16,7% | |
| 2025-08-25 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.336 | 13,42 | -31.349,12 | -20,0% | |
| 2025-08-22 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.942 | 13,22 | -38.901,48 | -24,8% | |
| 2025-08-22 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -2.362 | 13,22 | -31.232,25 | -19,9% | |
| 2025-08-22 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -1.864 | 13,22 | -24.647,30 | -15,7% | |
| 2025-08-22 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10.940 | 13,22 | -144.657,43 | -92,3% | |
| 2025-08-18 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -2.649 | 13,19 | -34.932,36 | -22,3% | |
| 2025-08-18 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.939 | 13,19 | -38.756,59 | -24,7% | |
| 2025-08-18 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -4.409 | 13,19 | -58.141,48 | -37,1% | |
| 2025-07-09 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -30.250 | 15,69 | -474.698,13 | -302,8% | |
| 2025-07-09 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -32.979 | 15,69 | -517.522,96 | -330,1% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Venrock Adviser, LLC | 6.474.485 | 6.728.985 | -254.500 | 130.331.383 | Reduziert | -3,8% | |
| Frazier Life Sciences Management, L.P. | 4.961.108 | 5.039.867 | -78.759 | 99.867.104 | Reduziert | -1,6% | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.768.712 | 4.768.712 | 0 | 95.994.173 | Unverändert | 0,0% | |
| TANG CAPITAL MANAGEMENT LLC | 4.573.530 | 4.573.530 | 0 | 92.065.159 | Unverändert | 0,0% | |
| BlackRock, Inc. | 3.795.897 | 3.754.148 | 41.749 | 76.411.406 | Aufgestockt | +1,1% | |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.876.407 | 2.717.718 | 158.689 | 57.902.073 | Aufgestockt | +5,8% | |
| Capital World Investors | 2.808.583 | 2.808.583 | 0 | 56.536.776 | Unverändert | 0,0% | |
| Caption Management, LLC | 2.430.000 | 117.907 | 2.312.093 | 48.915.900 | Aufgestockt | +1960,9% | |
| Point72 Asset Management, L.P. | 2.136.940 | 2.283.766 | -146.826 | 43.016.602 | Reduziert | -6,4% | |
| VANGUARD GROUP INC | 2.509.020 | 0 | 2.509.020 | 40.520.674 | Neu | +100,0% | |
| STATE STREET CORP | 1.955.844 | 1.911.691 | 44.153 | 39.371.140 | Aufgestockt | +2,3% | |
| MILLENNIUM MANAGEMENT LLC | 1.912.146 | 2.920.166 | -1.008.020 | 38.491.499 | Reduziert | -34,5% | |
| Vestal Point Capital, LP | 1.850.000 | 1.890.000 | -40.000 | 37.240.500 | Reduziert | -2,1% | |
| Parkman Healthcare Partners LLC | 1.835.506 | 1.768.508 | 66.998 | 36.948.736 | Aufgestockt | +3,8% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.830.467 | 0 | 1.830.467 | 36.847.301 | Neu | +100,0% | |
| Kynam Capital Management, LP | 1.820.954 | 1.810.954 | 10.000 | 36.655.804 | Aufgestockt | +0,6% | |
| Woodline Partners LP | 1.509.920 | 1.921.092 | -411.172 | 30.394.690 | Reduziert | -21,4% | |
| Octagon Capital Advisors LP | 1.450.000 | 1.273.333 | 176.667 | 29.188.500 | Aufgestockt | +13,9% | |
| EMERALD ADVISERS, LLC | 1.264.023 | 1.340.495 | -76.472 | 25.444.783 | Reduziert | -5,7% | |
| ARMISTICE CAPITAL, LLC | 1.236.000 | 800.000 | 436.000 | 24.880.680 | Aufgestockt | +54,5% | |
| Elmind Capital, LP | 1.021.300 | 801.300 | 220.000 | 20.558.769 | Aufgestockt | +27,5% | |
| GEODE CAPITAL MANAGEMENT, LLC | 996.235 | 944.077 | 52.158 | 20.059.823 | Aufgestockt | +5,5% | |
| Spruce Street Capital LP | 897.681 | 387.968 | 509.713 | 18.070.319 | Aufgestockt | +131,4% | |
| Freestone Grove Partners LP | 882.906 | 633.019 | 249.887 | 17.772.898 | Aufgestockt | +39,5% | |
| GOLDMAN SACHS GROUP INC | 824.293 | 835.304 | -11.011 | 16.593.018 | Reduziert | -1,3% | |
| EMERALD MUTUAL FUND ADVISERS TRUST | 805.762 | 855.461 | -49.699 | 16.219.989 | Reduziert | -5,8% | |
| GREAT POINT PARTNERS LLC | 675.000 | 685.632 | -10.632 | 13.587.750 | Reduziert | -1,6% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 564.039 | 0 | 564.039 | 11.354.105 | Neu | +100,0% | |
| Squadron Capital Management LLC | 700.000 | 0 | 700.000 | 11.305.000 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 555.628 | 389.813 | 165.815 | 11.184.791 | Aufgestockt | +42,5% | |
| BARCLAYS PLC | 537.061 | 700.573 | -163.512 | 10.811.038 | Reduziert | -23,3% | |
| UBS Group AG | 515.650 | 371.993 | 143.657 | 10.380.034 | Aufgestockt | +38,6% | |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 506.743 | 1.171.755 | -665.012 | 9.303.801 | Reduziert | -56,8% | |
| MORGAN STANLEY | 439.099 | 700.228 | -261.129 | 8.839.072 | Reduziert | -37,3% | |
| Catalio Capital Management, LP | 426.551 | 0 | 426.551 | 8.586.472 | Neu | +100,0% | |
| Hennion & Walsh Asset Management, Inc. | 375.995 | 341.819 | 34.176 | 7.568.779 | Aufgestockt | +10,0% | |
| NORTHERN TRUST CORP | 363.694 | 351.973 | 11.721 | 7.321.161 | Aufgestockt | +3,3% | |
| SEB Asset Management AB | 351.305 | 0 | 351.305 | 7.071.761 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 323.451 | 324.369 | -918 | 6.511.069 | Reduziert | -0,3% | |
| Schonfeld Strategic Advisors LLC | 315.537 | 305.880 | 9.657 | 6.351.758 | Aufgestockt | +3,2% | |
| Jefferies Financial Group Inc. | 286.046 | 0 | 286.046 | 5.758.106 | Neu | +100,0% | |
| Skandinaviska Enskilda Banken AB (publ) | 351.305 | 0 | 351.305 | 5.682.358 | Neu | +100,0% | |
| Ishara Investments LP | 276.750 | 0 | 276.750 | 5.570.978 | Neu | +100,0% | |
| DAFNA Capital Management LLC | 267.402 | 356.802 | -89.400 | 5.382.802 | Reduziert | -25,1% | |
| Atom Investors LP | 245.993 | 276.113 | -30.120 | 4.951.839 | Reduziert | -10,9% | |
| CITIGROUP INC | 244.261 | 10.771 | 233.490 | 4.916.974 | Aufgestockt | +2167,8% | |
| AMERIPRISE FINANCIAL INC | 229.984 | 34.929 | 195.055 | 4.629.577 | Aufgestockt | +558,4% | |
| F/m Investments LLC | 226.991 | 236.690 | -9.699 | 4.569.329 | Reduziert | -4,1% | |
| Blue Owl Capital Holdings LP | 215.000 | 360.000 | -145.000 | 4.327.950 | Reduziert | -40,3% | |
| FMR LLC | 187.848 | 111.807 | 76.041 | 3.781.383 | Aufgestockt | +68,0% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| Venrock Adviser, LLC | 6.474.485 | 6.728.985 | -3,8% | 130.331.383 | 9,36 |
| Frazier Life Sciences Management, L.P. | 4.961.108 | 5.039.867 | -1,6% | 99.867.104 | 7,17 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4.768.712 | 4.768.712 | 0,0% | 95.994.173 | 6,90 |
| TANG CAPITAL MANAGEMENT LLC | 4.573.530 | 4.573.530 | 0,0% | 92.065.159 | 6,61 |
| BlackRock, Inc. | 3.795.897 | 3.754.148 | +1,1% | 76.411.406 | 5,49 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.876.407 | 2.717.718 | +5,8% | 57.902.073 | 4,16 |
| Capital World Investors | 2.808.583 | 2.808.583 | 0,0% | 56.536.776 | 4,06 |
| Caption Management, LLC | 2.430.000 | 117.907 | +1960,9% | 48.915.900 | 3,51 |
| Point72 Asset Management, L.P. | 2.136.940 | 2.283.766 | -6,4% | 43.016.602 | 3,09 |
| STATE STREET CORP | 1.955.844 | 1.911.691 | +2,3% | 39.371.140 | 2,83 |
| MILLENNIUM MANAGEMENT LLC | 1.912.146 | 2.920.166 | -34,5% | 38.491.499 | 2,77 |
| Vestal Point Capital, LP | 1.850.000 | 1.890.000 | -2,1% | 37.240.500 | 2,68 |
| Parkman Healthcare Partners LLC | 1.835.506 | 1.768.508 | +3,8% | 36.948.736 | 2,65 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.830.467 | 0 | +100,0% | 36.847.301 | 2,65 |
| Kynam Capital Management, LP | 1.820.954 | 1.810.954 | +0,6% | 36.655.804 | 2,63 |
| Woodline Partners LP | 1.509.920 | 1.921.092 | -21,4% | 30.394.690 | 2,18 |
| Octagon Capital Advisors LP | 1.450.000 | 1.273.333 | +13,9% | 29.188.500 | 2,10 |
| EMERALD ADVISERS, LLC | 1.264.023 | 1.340.495 | -5,7% | 25.444.783 | 1,83 |
| ARMISTICE CAPITAL, LLC | 1.236.000 | 800.000 | +54,5% | 24.880.680 | 1,79 |
| Elmind Capital, LP | 1.021.300 | 801.300 | +27,5% | 20.558.769 | 1,48 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 184 | 73,9 | 1.482 |
| 31.12.2025 | ✓ | 161 | 68,7 | 1.103 |
| 30.09.2025 | ✓ | 150 | 63,8 | 753 |
| 30.06.2025 | ✓ | 137 | 56,1 | 628 |
| 31.03.2025 | ✓ | 131 | 58,4 | 670 |
| 31.12.2024 | ✓ | 128 | 56,6 | 477 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Point72 Asset Management, L.P. | 2.283.766 | 36.882.821 |
| Elmind Capital, LP | 801.300 | 12.940.995 |
| ARMISTICE CAPITAL, LLC | 800.000 | 12.920.000 |
| Squadron Capital Management LLC | 700.000 | 11.305.000 |
| GREAT POINT PARTNERS LLC | 685.632 | 11.072.957 |
| Spruce Street Capital LP | 387.968 | 6.265.683 |
| ORBIMED ADVISORS LLC | 382.400 | 6.175.760 |
| Atom Investors LP | 276.113 | 4.459.225 |
| RENAISSANCE TECHNOLOGIES LLC | 165.151 | 2.667.189 |
| NEXTBio Capital Management LP | 131.796 | 2.128.505 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.717.718 | 1.354.340 | +99.3 % | 43.891.146 |
| Kynam Capital Management, LP | 1.810.954 | 1.204.783 | +198.8 % | 29.246.907 |
| Vestal Point Capital, LP | 1.890.000 | 1.140.000 | +152.0 % | 30.523.500 |
| MILLENNIUM MANAGEMENT LLC | 2.920.166 | 803.943 | +38.0 % | 47.160.681 |
| BlackRock, Inc. | 3.754.148 | 628.031 | +20.1 % | 60.629.492 |
| STATE STREET CORP | 1.911.691 | 336.195 | +21.3 % | 30.873.810 |
| Blue Owl Capital Holdings LP | 360.000 | 235.000 | +188.0 % | 5.814.000 |
| Hennion & Walsh Asset Management, Inc. | 341.819 | 165.236 | +93.6 % | 5.520.377 |
| Skandinaviska Enskilda Banken AB (publ) | 351.305 | 150.314 | +74.8 % | 5.682.358 |
| MORGAN STANLEY | 700.228 | 135.372 | +24.0 % | 11.308.696 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Caption Management, LLC | 117.907 | -1.469.715 | -92.6 % | 1.904.198 |
| GOLDMAN SACHS GROUP INC | 835.304 | -964.877 | -53.6 % | 13.490.160 |
| TANG CAPITAL MANAGEMENT LLC | 4.573.530 | -468.268 | -9.3 % | 73.862.510 |
| Capital World Investors | 2.808.583 | -369.004 | -11.6 % | 45.358.615 |
| Ikarian Capital, LLC | 35.119 | -364.881 | -91.2 % | 567.173 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 125.595 | -279.644 | -69.0 % | 2.028.359 |
| CITIGROUP INC | 10.771 | -269.885 | -96.2 % | 173.952 |
| Schonfeld Strategic Advisors LLC | 305.880 | -140.492 | -31.5 % | 4.939.959 |
| PANAGORA ASSET MANAGEMENT INC | 109.391 | -87.944 | -44.6 % | 1.766.665 |
| UBS Group AG | 371.993 | -82.155 | -18.1 % | 6.007.687 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 10.06.2026 | Glazer Capital, LLC | Passiv (13G) | 4,85 % | 2.581.700 | Neu | |
| 10.06.2026 | Paul J. Glazer | Passiv (13G) | 4,85 % | 2.581.700 | Neu | |
| 21.05.2026 | FHMLS X, L.L.C. | Aktivist (13D/A) | 0,80 % | 427.983 | -1,50 pp | |
| 21.05.2026 | Frazier Life Sciences XI, L.P. | Aktivist (13D/A) | 0,30 % | 145.592 | -0,50 pp | |
| 21.05.2026 | FHMLS XII, L.P. | Aktivist (13D/A) | 0,00 % | 6.563 | Neu | |
| 21.05.2026 | FHMLSP, L.P. | Aktivist (13D/A) | 2,30 % | 1.249.165 | -4,60 pp | |
| 21.05.2026 | Frazier Life Sciences XII, L.P. | Aktivist (13D/A) | 0,00 % | 6.563 | Neu | |
| 21.05.2026 | FHMLSP, L.L.C. | Aktivist (13D/A) | 2,30 % | 1.249.165 | -4,60 pp | |
| 21.05.2026 | FHMLS XII, L.L.C. | Aktivist (13D/A) | 0,00 % | 6.563 | Neu | |
| 21.05.2026 | Frazier Life Sciences X, L.P. | Aktivist (13D/A) | 0,80 % | 427.983 | -1,50 pp | |
| 21.05.2026 | FHMLS XI, L.P. | Aktivist (13D/A) | 0,30 % | 145.592 | -0,50 pp | |
| 21.05.2026 | James N. Topper | Aktivist (13D/A) | 0,80 % | 427.983 | -1,50 pp | |
| 21.05.2026 | Patrick J. Heron | Aktivist (13D/A) | 0,80 % | 427.983 | -1,50 pp | |
| 21.05.2026 | FHMLS X, L.P. | Aktivist (13D/A) | 0,80 % | 427.983 | -1,50 pp | |
| 21.05.2026 | Frazier Life Sciences Public Fund, L.P. | Aktivist (13D/A) | 2,30 % | 1.249.165 | -4,60 pp | |
| 21.05.2026 | FHMLS XI, L.L.C. | Aktivist (13D/A) | 0,80 % | 145.592 | 0,00 pp | |
| 15.05.2026 | Steven A. Cohen | Passiv (13G/A) | 4,20 % | 2.136.940 | -1,30 pp | |
| 15.05.2026 | Point72 Capital Advisors, Inc. | Passiv (13G/A) | 4,20 % | 2.136.940 | -1,30 pp | |
| 15.05.2026 | Point72 Asset Management, L.P. | Passiv (13G/A) | 4,20 % | 2.136.940 | -1,30 pp | |
| 13.05.2026 | SilverArc Capital Management, LLC | Passiv (13G) | 5,60 % | 2.876.407 | Neu | |
| 13.05.2026 | Devesh Gandhi | Passiv (13G) | 5,60 % | 2.876.407 | Neu | |
| 01.05.2026 | Integrated Core Strategies (US) LLC | Passiv (13G/A) | 3,00 % | 1.546.105 | -2,10 pp | |
| 01.05.2026 | Millennium Management LLC | Passiv (13G/A) | 3,70 % | 1.912.146 | -2,20 pp | |
| 01.05.2026 | Millennium Group Management LLC | Passiv (13G/A) | 3,70 % | 1.912.146 | -2,20 pp | |
| 01.05.2026 | Israel A. Englander | Passiv (13G/A) | 3,70 % | 1.912.146 | -2,20 pp | |
| 13.01.2026 | Steven A. Cohen | Passiv (13G/A) | 5,50 % | 2.781.902 | +0,60 pp | |
| 13.01.2026 | Point72 Capital Advisors, Inc. | Passiv (13G/A) | 5,50 % | 2.781.902 | +0,60 pp | |
| 13.01.2026 | Point72 Asset Management, L.P. | Passiv (13G/A) | 5,50 % | 2.781.902 | +0,60 pp | |
| 12.01.2026 | Steven A. Cohen | Passiv (13G) | 4,90 % | 2.523.493 | Neu | |
| 12.01.2026 | Point72 Asset Management, L.P. | Passiv (13G) | 4,90 % | 2.523.493 | Neu | |
| 12.01.2026 | Point72 Capital Advisors, Inc. | Passiv (13G) | 4,90 % | 2.523.493 | Neu | |
| 30.12.2025 | Integrated Core Strategies (US) LLC | Passiv (13G/A) | 5,10 % | 2.588.344 | Neu | |
| 30.12.2025 | Millennium Group Management LLC | Passiv (13G/A) | 5,90 % | 2.963.699 | +0,90 pp | |
| 30.12.2025 | Millennium Management LLC | Passiv (13G/A) | 5,90 % | 2.963.699 | +0,90 pp | |
| 30.12.2025 | Israel A. Englander | Passiv (13G/A) | 5,90 % | 2.963.699 | +0,90 pp | |
| 14.11.2025 | Vestal Point Capital, LP | Passiv (13G/A) | 1,50 % | 750.000 | -7,80 pp | |
| 14.11.2025 | Ryan Wilder | Passiv (13G/A) | 1,50 % | 750.000 | -7,80 pp | |
| 10.11.2025 | Millennium Group Management LLC | Passiv (13G) | 5,00 % | 2.531.010 | Neu | |
| 10.11.2025 | Millennium Management LLC | Passiv (13G) | 5,00 % | 2.531.010 | Neu | |
| 10.11.2025 | Israel A. Englander | Passiv (13G) | 5,00 % | 2.531.010 | Neu |
Stammdaten
KalVista Pharmaceuticals, Inc., ein Pharmaunternehmen im klinischen Stadium, erforscht, entwickelt und vermarktet kleine-Molekül-Proteaseinhibitoren für Erkrankungen mit ungedecktem Bedarf. Das Produktportfolio des Unternehmens umfasst kleine-Molekül-Plasmakallikrein-Inhibitoren, die auf hereditäres Angioödem (HAE) und diabetisches Makulaödem (DME) abzielen; sowie orale Plasmakallikrein-Inhibitoren. Seine Produkte umfassen KVD001, einen Plasmakallikrein-Inhibitor, der eine Phase-II-Klinische Studie für die Behandlung von DME abgeschlossen hat; Sebetralstat, bei dem die Phase-3-KONFIDENT-Studie als potenzielle orale Bedarfstherapie für HAE-Anfälle eingeleitet wird; KVD824, einen oralen Produktkandidaten für die Behandlung von HAE; und Factor XIIa, ein orales Inhibitor-Programm, das sich in präklinischer Phase befindet und auf ein Enzym bei HAE abzielt. Das Unternehmen hat seinen Sitz in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | KalVista Pharmaceuticals, Inc. |
|---|---|
| Ticker | KALV |
| CIK | 0001348911 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 483497103 |
|---|---|
| ISIN | US4834971032 |
| Typ | Common Stock |
| Marktkapitalisierung | 1,34 Mrd. USD |
| Beta | -0,11 |
Bewertung
| KBV (P/B) | 14,08 vs. 2,37 (2021) ▲ |
|---|---|
| FCF-Rendite | -11,4 % vs. -5,0 % (2021) ▼ |
Qualität & Bilanz
| ROIC | -180,4 % vs. -17,6 % (2021) ▼ |
|---|---|
| Zinsdeckungsgrad | -32,5 |
Basis: SEC-XBRL-Jahresabschluss bis 30.04.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 2,37 | 1,69 | 1,81 | 2,34 | 7,18 | |
| FCF-Rendite | -5,0 % | -25,3 % | -26,2 % | -18,5 % | -22,4 % | |
| Qualität & Bilanz | ||||||
| ROIC | -17,6 % | -42,6 % | -54,9 % | -59,2 % | -180,4 % | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 40.863.000 | -23.487.000 | -0,43 | 328.917.000 | -19.652.000 |
| 2025-09-30 | 10-Q | 13.700.000 | -49.482.000 | -0,92 | 339.931.000 | 16.999.000 |
| 2025-07-31 | 10-Q | 1.400.000 | -60.096.000 | -1,12 | 215.505.000 | 40.790.000 |
| 2025-06-30 | 10-Q | -57.596.000 | 59.445.000 | |||
| 2025-04-30 | 10-K | -183.444.000 | -3,69 | 250.770.000 | 95.391.000 | |
| 2025-04-30 | 10-Q | 11.000.000 | 250.770.000 | 95.391.000 | ||
| 2025-03-31 | 10-Q | -51.836.000 | -0,98 | 116.758.000 | ||
| 2025-01-31 | 10-Q | -48.509.000 | -0,92 | 275.993.000 | 145.126.000 | |
| 2024-10-31 | 10-Q | -42.268.000 | -0,91 | 160.831.000 | 133.992.000 | |
| 2024-09-30 | 10-Q | 0 | -39.084.000 | -0,84 | 148.530.000 | |
| 2024-07-31 | 10-Q | 0 | -40.443.000 | -0,87 | 200.198.000 | 172.799.000 |
| 2024-06-30 | 10-Q | -40.340.000 | 180.927.000 | |||
| 2024-04-30 | 10-K | 50.000.000 | -126.644.000 | -3,44 | 235.404.000 | 206.582.000 |
| 2024-03-31 | 10-Q | -43.105.000 | 217.602.000 | |||
| 2024-01-31 | 10-Q | -29.028.000 | -0,84 | 113.968.000 | 88.583.000 | |
| 2023-10-31 | 10-Q | -27.650.000 | -0,80 | 138.743.000 | 114.446.000 | |
| 2023-07-31 | 10-Q | -25.317.000 | -0,74 | 160.332.000 | 139.335.000 | |
| 2023-04-30 | 10-K | -92.907.000 | -3,33 | 183.202.000 | 161.025.000 | |
| 2023-01-31 | 10-Q | -21.303.000 | -0,75 | 203.468.000 | 184.441.000 | |
| 2022-10-31 | 10-Q | -22.257.000 | -0,90 | 162.838.000 | 143.813.000 |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| 2026 | 31.03.2026 | 14.05.2026 | 40,9 Mio. USD | -0,43 |
| 2025 | 30.09.2025 | 10.11.2025 | 13,7 Mio. USD | -0,92 |
| Q1 2025 | 31.07.2025 | 11.09.2025 | 1,4 Mio. USD | -1,12 |
| 2025 | 31.03.2025 | 14.05.2026 | – | -0,98 |
| Q3 2025 | 31.01.2025 | 12.03.2025 | – | -0,92 |
| Q2 2024 | 31.10.2024 | 12.03.2025 | – | -0,91 |
| 2024 | 30.09.2024 | 10.11.2025 | 0 USD | -0,84 |
| Q1 2024 | 31.07.2024 | 11.09.2025 | 0 USD | -0,87 |
| Q3 2024 | 31.01.2024 | 12.03.2025 | – | -0,84 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 14.05.2026 | 10-Q | – | – | SEC » |
| 10.11.2025 | 10-Q | 30.09.2025 | 41 Tage | SEC » |
| 11.09.2025 | 10-Q | 31.07.2025 | 42 Tage | SEC » |
| 10.07.2025 | 10-K | 30.04.2025 | 71 Tage | SEC » |
| 12.03.2025 | 10-Q | 31.01.2025 | 40 Tage | SEC » |
| 05.12.2024 | 10-Q | 31.10.2024 | 35 Tage | SEC » |
| 05.09.2024 | 10-Q | 31.07.2024 | 36 Tage | SEC » |
| 11.07.2024 | 10-K | 30.04.2024 | 72 Tage | SEC » |
| 11.03.2024 | 10-Q | 31.01.2024 | 40 Tage | SEC » |
| 07.12.2023 | 10-Q | 31.10.2023 | 37 Tage | SEC » |
| 07.09.2023 | 10-Q | 31.07.2023 | 38 Tage | SEC » |
| 10.07.2023 | 10-K | 30.04.2023 | 71 Tage | SEC » |
| 09.03.2023 | 10-Q | 31.01.2023 | 37 Tage | SEC » |
| 08.12.2022 | 10-Q | 31.10.2022 | 38 Tage | SEC » |
| 08.09.2022 | 10-Q | 31.07.2022 | 39 Tage | SEC » |
| 07.07.2022 | 10-K | 30.04.2022 | 68 Tage | SEC » |
| 10.03.2022 | 10-Q | 31.01.2022 | 38 Tage | SEC » |
| 09.12.2021 | 10-Q | 31.10.2021 | 39 Tage | SEC » |
| 09.09.2021 | 10-Q | 31.07.2021 | 40 Tage | SEC » |
| 13.07.2021 | 10-K | 30.04.2021 | 74 Tage | SEC » |
| 11.03.2021 | 10-Q | 31.01.2021 | 39 Tage | SEC » |
| 10.12.2020 | 10-Q | 31.10.2020 | 40 Tage | SEC » |
| 14.09.2020 | 10-Q | 31.07.2020 | 45 Tage | SEC » |
| 01.07.2020 | 10-K | 30.04.2020 | 62 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (11.06.2026)
HOCH Abgang Schlüsselpersonen (11.06.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 11.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 and Item 5.03 are incorporated herein by reference. As a result of the consummation of the Offer and the… |
| 10.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 22.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 14.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 05.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 17.10.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 27.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 19.03.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-13 | 21.201 | 26,73 | 566.703 |
| 2026-05-07 | 20 | 26,72 | 534 |
| 2026-05-06 | 27.035 | 26,71 | 722.105 |
| 2026-05-05 | 8.846 | 26,66 | 235.834 |
| 2026-05-04 | 824 | 26,65 | 21.960 |
| 2026-04-30 | 125.753 | 26,67 | 3.353.833 |
| 2026-04-28 | 20.791 | 19,16 | 398.356 |
| 2026-04-27 | 5 | 19,63 | 98 |
| 2026-04-17 | 189.118 | 19,56 | 3.699.148 |
| 2026-04-15 | 1 | 20,29 | 20 |
| 2026-04-08 | 5.265 | 20,12 | 105.932 |
| 2026-04-07 | 163.514 | 20,19 | 3.301.348 |
| 2026-04-06 | 184.602 | 19,90 | 3.673.580 |
| 2026-04-02 | 38.493 | 19,77 | 761.007 |
| 2026-04-01 | 509 | 20,13 | 10.246 |
| 2026-03-31 | 90.142 | 18,36 | 1.655.007 |
| 2026-03-30 | 8.045 | 19,33 | 155.510 |
| 2026-03-27 | 87.790 | 18,95 | 1.663.621 |
| 2026-03-26 | 21.908 | 17,14 | 375.503 |
| 2026-03-23 | 42.979 | 17,00 | 730.643 |
| 2026-03-20 | 1.465 | 16,43 | 24.070 |
| 2026-03-16 | 212.727 | 16,94 | 3.603.595 |
| 2026-03-13 | 17.198 | 17,38 | 298.901 |
| 2026-03-12 | 14.733 | 18,24 | 268.730 |
| 2026-03-11 | 13.049 | 18,44 | 240.624 |
| 2026-03-10 | 15.751 | 17,30 | 272.492 |
| 2026-03-09 | 32.370 | 16,23 | 525.365 |
| 2026-03-06 | 45.845 | 16,21 | 743.147 |
| 2026-03-05 | 22.124 | 16,37 | 362.170 |
| 2026-03-04 | 8.957 | 15,61 | 139.819 |
| 2026-03-03 | 40.094 | 16,06 | 643.910 |
| 2026-03-02 | 697 | 16,28 | 11.347 |
| 2026-02-27 | 3.017 | 15,76 | 47.548 |
| 2026-02-26 | 771 | 15,76 | 12.151 |
| 2026-02-24 | 1.119 | 15,56 | 17.412 |
| 2026-02-20 | 5.086 | 15,89 | 80.817 |
| 2026-02-18 | 3.911 | 14,99 | 58.626 |
| 2026-02-17 | 2.376 | 14,91 | 35.426 |
| 2026-02-13 | 717 | 15,12 | 10.841 |
| 2026-02-12 | 8.288 | 15,51 | 128.547 |
| 2026-02-11 | 256 | 15,01 | 3.843 |
| 2026-02-09 | 4.548 | 14,90 | 67.765 |
| 2026-02-06 | 176 | 14,40 | 2.534 |
| 2026-02-05 | 6.857 | 14,98 | 102.718 |
| 2026-02-03 | 24.109 | 16,11 | 388.396 |
| 2026-02-02 | 5.562 | 15,61 | 86.823 |
| 2026-01-28 | 51.251 | 14,94 | 765.690 |
| 2026-01-23 | 3.050 | 16,54 | 50.447 |
| 2026-01-22 | 107.781 | 15,91 | 1.714.796 |
| 2026-01-21 | 56.207 | 15,31 | 860.529 |
| 2026-01-20 | 143.432 | 14,60 | 2.094.107 |
| 2026-01-12 | 71.856 | 16,80 | 1.207.181 |
| 2026-01-05 | 536 | 15,46 | 8.287 |
| 2025-12-31 | 7.088 | 15,68 | 111.140 |
| 2025-12-30 | 375 | 15,17 | 5.689 |
| 2025-12-17 | 8.467 | 15,90 | 134.625 |
| 2025-12-16 | 86 | 16,90 | 1.453 |